{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:50:05Z","timestamp":1788274205537,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience & Biobehavioral Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.neubiorev.2026.106573","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T16:10:31Z","timestamp":1769271031000},"page":"106573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"183","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4027-5223","authenticated-orcid":false,"given":"Omer A.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Nestor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Lipsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ishrat","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Giacobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.neubiorev.2026.106573_bib1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.encep.2020.12.002","article-title":"Efficacy of psychedelics in psychiatry, a systematic review of the literature","volume":"47","author":"Berkovitch","year":"2021","journal-title":"L'Enceph"},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106573_bib2","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.20230643","article-title":"Pharmacological and nonpharmacological components of psychedelic treatments: the whole is not the sum of the parts","volume":"181","author":"Bogenschutz","year":"2024","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2026.106573_bib3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s11121-013-0377-7","article-title":"Meta-analysis and subgroups","volume":"14","author":"Borenstein","year":"2013","journal-title":"Prev. Sci."},{"issue":"9","key":"10.1016\/j.neubiorev.2026.106573_bib4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40263-020-00748-y","article-title":"Psychedelic treatments for psychiatric disorders: A systematic review and thematic synthesis of patient experiences in qualitative studies","volume":"34","author":"Breeksema","year":"2020","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.neubiorev.2026.106573_bib5","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/0269881118754710","article-title":"Psychedelics and the essential importance of context","volume":"32","author":"Carhart-Harris","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"15","key":"10.1016\/j.neubiorev.2026.106573_bib6","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.neubiorev.2026.106573_bib7","first-page":"16","article-title":"Real-world data on SSRI antidepressant side effects","volume":"6","author":"Cascade","year":"2009","journal-title":"Psychiatry (Edgmont)"},{"issue":"5","key":"10.1016\/j.neubiorev.2026.106573_bib8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2026.106573_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/02791072.2019.1606472","article-title":"The past and future of psychedelic science: an introduction to this issue","volume":"51","author":"Doblin","year":"2019","journal-title":"J. Psychoact. Drugs"},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106573_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/02791072.2022.2047842","article-title":"How important is a guide who has taken psilocybin in psilocybin-assisted therapy for depression?","volume":"55","author":"Earleywine","year":"2023","journal-title":"J. Psychoact. Drugs"},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106573_bib11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1176\/appi.ajp.20230572","article-title":"Psilocybin without psychotherapy: a cart without a horse?","volume":"181","author":"Earleywine","year":"2024","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2026.106573_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/00221678221085800","article-title":"Integration in psychedelic-assisted treatments: Recurring themes in current providers\u2019 definitions, challenges, and concerns","author":"Earleywine","year":"2022","journal-title":"J. Humanist. Psychol."},{"issue":"4","key":"10.1016\/j.neubiorev.2026.106573_bib13","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1017\/S0963180123000099","article-title":"Is the requirement for first-person experience of psychedelic drugs a justified component of a psychedelic therapist\u2019s training?","volume":"33","author":"Emmerich","year":"2024","journal-title":"Camb. Q. Healthc. Ethics"},{"key":"10.1016\/j.neubiorev.2026.106573_bib14","first-page":"1","article-title":"Rapid and sustained antidepressant effects of vaporized N, N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression","author":"Falchi-Carvalho","year":"2025","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neubiorev.2026.106573_bib15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00213-020-05719-1","article-title":"Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants","volume":"238","author":"Galv\u00e3o-Coelho","year":"2021","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.neubiorev.2026.106573_bib16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0269881121991822","article-title":"Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches","volume":"35","author":"Garcia-Romeu","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.neubiorev.2026.106573_bib17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.bpsc.2023.11.003","article-title":"A brief historical overview of psychedelic research","volume":"9","author":"Geyer","year":"2024","journal-title":"Biological Psychiatry Cognitive Neuroscience Neuroimaging"},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106573_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s44184-024-00065-y","article-title":"Disability rights and experiential use of psychedelics in clinical research and practice","volume":"3","author":"Golafshani","year":"2024","journal-title":"Npj Ment. Health Res."},{"key":"10.1016\/j.neubiorev.2026.106573_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.112749","article-title":"The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis","volume":"284","author":"Goldberg","year":"2020","journal-title":"Psychiatry Res."},{"issue":"18","key":"10.1016\/j.neubiorev.2026.106573_bib20","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neubiorev.2026.106573_bib21","article-title":"Must psilocybin always \u201cassist psychotherapy\u201d?","author":"Goodwin","year":"2023","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2026.106573_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2125.2004.02157.x","article-title":"What is the best size descriptor to use for pharmacokinetic studies in the obese?","volume":"58","author":"Green","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.neubiorev.2026.106573_bib23","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2026.106573_bib24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S2215-0366(23)00363-2","article-title":"Treatment with psychedelics is psychotherapy: beyond reductionism","volume":"11","author":"Gr\u00fcnder","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.neubiorev.2026.106573_bib25","doi-asserted-by":"crossref","unstructured":"Guss, J., Krause, R., & Sloshower, J. (2020). The Yale manual for psilocybin-assisted therapy of depression (using acceptance and commitment therapy as a therapeutic frame).","DOI":"10.31234\/osf.io\/u6v9y"},{"key":"10.1016\/j.neubiorev.2026.106573_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115531","article-title":"Psilocybin-assisted therapy for depression: A systematic review and meta-analysis","author":"Haikazian","year":"2023","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neubiorev.2026.106573_bib27","series-title":"Doing meta-analysis with R: A hands-on guide","author":"Harrer","year":"2021"},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106573_bib28","first-page":"10618","article-title":"Long-term acute-phase treatment with antidepressants, 8 weeks and beyond: a systematic review and meta-analysis of randomized, placebo-controlled trials","volume":"79","author":"Henssler","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neubiorev.2026.106573_bib29","unstructured":"Higgins J.P.T., et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from \u3008www.training.cochrane.org\/handbook\u3009."},{"key":"10.1016\/j.neubiorev.2026.106573_bib30","series-title":"Cochrane handbook for systematic reviews of interventions","year":"2008"},{"issue":"11","key":"10.1016\/j.neubiorev.2026.106573_bib31","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"issue":"7","key":"10.1016\/j.neubiorev.2026.106573_bib32","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/02698811231180276","article-title":"Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review","volume":"37","author":"Hovmand","year":"2023","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106573_bib33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1176\/appi.ajp.20230884","article-title":"Compass psychological support model for COMP360 psilocybin treatment of serious mental health conditions","volume":"182","author":"Kirli\u0107","year":"2024","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.neubiorev.2026.106573_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.917199","article-title":"Psychedelics, mystical experience, and therapeutic efficacy: a systematic review","volume":"13","author":"Ko","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neubiorev.2026.106573_bib35","first-page":"3","article-title":"The increasing burden of depression","volume":"7","author":"L\u00e9pine","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"3","key":"10.1016\/j.neubiorev.2026.106573_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0300501","article-title":"The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder","volume":"19","author":"Levin","year":"2024","journal-title":"Plos One"},{"key":"10.1016\/j.neubiorev.2026.106573_bib37","article-title":"The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis","author":"Li","year":"2025","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neubiorev.2026.106573_bib38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jad.2021.09.041","article-title":"Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis","volume":"296","author":"Li","year":"2022","journal-title":"Journal of Affective Disorders"},{"issue":"12","key":"10.1016\/j.neubiorev.2026.106573_bib39","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jama.2024.13370","article-title":"Psychedelic therapy scrutinized by FDA advisory committee?","volume":"332","author":"Marks","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.neubiorev.2026.106573_bib40","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jad.2020.07.045","article-title":"Burden of Treatment Resistant Depression (TRD) in patients with major depressive disorder in Ontario using Institute for Clinical Evaluative Sciences (ICES) databases: Economic burden and healthcare resource utilization","volume":"277","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106573_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-018-1824-6","article-title":"Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature","volume":"18","author":"Michaels","year":"2018","journal-title":"BMC Psychiatry"},{"issue":"12","key":"10.1016\/j.neubiorev.2026.106573_bib42","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3928\/00485713-20221123-01","article-title":"Racial disparities in access to psychedelic treatments and inclusion in research trials","volume":"52","author":"Morales","year":"2022","journal-title":"Psychiatr. Ann."},{"key":"10.1016\/j.neubiorev.2026.106573_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.788155","article-title":"Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression","volume":"12","author":"Murphy","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.neubiorev.2026.106573_bib44","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106573_bib45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1176\/appi.ajp.20230661","article-title":"Misinterpretations and omissions: a critical response to Goodwin and colleagues\u2019 commentary on psilocybin-assisted therapy","volume":"181","author":"O\u2019Donnell","year":"2024","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2026.106573_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int. J. Surg."},{"issue":"9","key":"10.1016\/j.neubiorev.2026.106573_bib47","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"Jama"},{"key":"10.1016\/j.neubiorev.2026.106573_bib48","unstructured":"Rohatgi, A. (2017, June). WebPlotDigitizer. Accessed at: https:\/\/apps.automeris.io\/wpd4\/."},{"key":"10.1016\/j.neubiorev.2026.106573_bib49","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neubiorev.2026.106573_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.01.005","article-title":"Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin","author":"Rosenblat","year":"2024","journal-title":"Med"},{"issue":"11","key":"10.1016\/j.neubiorev.2026.106573_bib51","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2026.106573_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fsoc.2023.1114523","article-title":"Historicizing psychedelics: counterculture, renaissance, and the neoliberal matrix","volume":"8","author":"Sanchez Petrement","year":"2023","journal-title":"Front. Sociol."},{"issue":"9","key":"10.1016\/j.neubiorev.2026.106573_bib53","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/02698811231190858","article-title":"Psilocybin history, action and reaction: A narrative clinical review","volume":"37","author":"Sharma","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2026.106573_bib54","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcbs.2019.11.002","article-title":"Psilocybin-assisted therapy of major depressive disorder using acceptance and commitment therapy as a therapeutic frame","volume":"15","author":"Sloshower","year":"2020","journal-title":"J. Context. Behav. Sci."},{"issue":"7","key":"10.1016\/j.neubiorev.2026.106573_bib55","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1177\/02698811231154852","article-title":"Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial","volume":"37","author":"Sloshower","year":"2023","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106573_bib56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/02698811221131994","article-title":"Body mass index (BMI) does not predict responses to psilocybin","volume":"37","author":"Spriggs","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2026.106573_bib57","doi-asserted-by":"crossref","DOI":"10.1177\/02698811251353250","article-title":"Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics","author":"Swieczkowski","year":"2025","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neubiorev.2026.106573_bib58","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jrsm.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"Viechtbauer","year":"2010","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.neubiorev.2026.106573_bib59","doi-asserted-by":"crossref","DOI":"10.1177\/02698811251389581","article-title":"Predictors of therapeutic response to psychedelic-assisted therapy: A systematic review","author":"Viljoen","year":"2025","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2026.106573_bib60","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"von Rotz","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.neubiorev.2026.106573_bib61","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jcbs.2019.12.004","article-title":"The use of the psychological flexibility model to support psychedelic assisted therapy","volume":"15","author":"Watts","year":"2020","journal-title":"J. Context. Behav. Sci."},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106573_bib62","doi-asserted-by":"crossref","DOI":"10.1080\/20008066.2023.2297536","article-title":"Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder","volume":"15","author":"Zeifman","year":"2024","journal-title":"Eur. J. Psychotraumatol."},{"key":"10.1016\/j.neubiorev.2026.106573_bib63","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.euroneuro.2023.09.007","article-title":"Methodological concerns in psychedelic research: The issues of nonequivalent psychological support and generalizability","volume":"78","author":"Zeifman","year":"2023","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."}],"container-title":["Neuroscience & Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014976342600028X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014976342600028X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:40:04Z","timestamp":1770673204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014976342600028X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":63,"alternative-id":["S014976342600028X"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2026.106573","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2026.106573","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106573"}}